These studies demonstrate that in p53-mutant breast cancers, E2F1A and FOXM1 regulates the expression of MELK, a novel kinase associated with poor prognosis and a potential novel target for the treatment of these aggressive cancers. Here, TP53 is linked to breast carcinoma.